Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2016 December;58(4) > Panminerva Medica 2016 December;58(4):286-93

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

PANMINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6


eTOC

 

REVIEWS  


Panminerva Medica 2016 December;58(4):286-93

language: English

Management of proliferative lupus nephritis

Jose M. MONROY TRUJILLO , Derek M. FINE

Division of Nephrology, Johns Hopkins Hospital, Baltimore, MD, USA


PDF  


Kidney abnormalities are present in up to 60% of patients with systemic lupus. Proliferative lupus nephritis is one of the most serious manifestation and requires rapid recognition and treatment. Kidney biopsy plays an essential role in the management and prognosis of proliferative lupus nephritis. Treatment includes and induction phase with systemic steroids and antiproliferative therapy. This is followed by a maintenance phase to prevent the risk of relapses. Cytotoxic therapy carries significant side effects and complications. Further research is needed to establish the role of biologics in the management of proliferative lupus nephritis.

top of page

Publication History

Cite this article as

Corresponding author e-mail

jmonroy2@jhmi.edu.